GTCR INVESTMENT XI LLC
Known title: DirectorCIK: 0001827977
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript. Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.
Transaction History
| SHC | ▼ Sell | Open Market | 12,735,301 | $193.2M | 5/13/2026 | View on chart |
| SHC | ▼ Sell | Open Market | 10,000,000 | $152.7M | 3/6/2026 | View on chart |
| SHC | ▼ Sell | Open Market | 6,480,000 | $105.8M | 12/3/2025 | View on chart |
| SHC | ▼ Sell | Open Market | 12,000,000 | $187.8M | 11/10/2025 | View on chart |
| SHC | ▼ Sell | Open Market | 8,000,000 | $120.9M | 9/5/2025 | View on chart |
| SHC | ▼ Sell | Open Market | 10,000,000 | $150.3M | 9/6/2024 | View on chart |
| MRVI | ▼ Sell | Other | 8,409,946 | — | 5/28/2024 | View on chart |
| MRVI | ▼ Sell | Other | 8,409,946 | — | 5/28/2024 | View on chart |
| MRVI | ▼ Sell | Open Market | 9,940,974 | $97.6M | 5/28/2024 | View on chart |
| SHC | ▼ Sell | Open Market | 11,062,908 | $158.3M | 3/4/2024 | View on chart |
| MRVI | ▼ Sell | Other | 4,575,170 | $0 | 1/22/2023 | View on chart |
| MRVI | ▼ Sell | Other | 2,570,415 | $0 | 12/31/2021 | View on chart |
| MRVI | ▼ Sell | Other | 17,068,559 | — | 9/9/2021 | View on chart |
| MRVI | ▼ Sell | Other | 2,931,441 | $146.6M | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17
JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.